jnj-77242113
janssen
['psoriasis', 'frontier 1']
an investigational il-23r antagonist demonstrated significantly greater efficacy across all doses in patients with moderate to severe #psoriasis compared with placebo at week 16 in the frontier 1 study. #wcd2023singapore #wcd2023 
MD  MS FACP Neurosurgeon
ICR researcher in Cancer Genomics. #KCL Alumni. #NHS reg Dr. CRUK 
https://t.co/oxznFwqqLA research lead. Currently relate with Erasmus MC